NACLC 2022 | Advances in EFGR-mutant NSCLC treatment

Biagio Ricciuti, MD, Dana-Farber Cancer Institute, Boston, MA, gives an overview of current developments in the treatment landscape for EFGR-mutant non-small cell lung cancer (NSCLC). Osimertinib is the standard of care for this subset of lung cancer and novel therapies include the bispecific antibody amivantamab, the third generation tyrosine kinase inhibitor (TKI), as well as antibody-drug conjugates (ADCs). Patients with EGFR exon 20 insertion mutations additionally have poorer prognoses, with amivantamab and mobocertinib showing promise in this group of patients. This interview took place at the IASLC 2022 North America Conference on Lung Cancer (NACLC 2022).

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.